HMOX1 and fetal growth restriction: CO might be used therapeutically to suppress early and recurrent onset of spontaneous abortions or fetal deaths associated with human HMOX1 polymorphisms (Otterbein et al., 2000) or to prevent IUGR in pre-eclampsia-associated with low HO-1 levels (Barber et al., 2001).